Pilot study on the immunogenicity of paired Env immunogens from mother-to-child transmitted HIV-1 isolates

References

• UNAIDS Report on the Global AIDS Epidemic. 2010. Joint United Nations Programme on HIV/AIDS (UNAIDS). http://wwwunaidsorg/globalreport/defaulthtm.
   Google Scholar
• Quinn TC, Overbaugh J. HIV/AIDS in women: an expanding epidemic. Science 2005; 308:1582 - 3; http://dx.doi.org/10.1126/science.1112489; PMID: 15947174
   PubMed Web of Science ®Google Scholar
• Luzuriaga K, Sullivan JL. Pediatric HIV-1 infection: advances and remaining challenges. AIDS Rev 2002; 4:21 - 6; PMID: 11998780
   PubMedGoogle Scholar
• Ahmad N, Baroudy BM, Baker RC, Chappey C. Genetic analysis of human immunodeficiency virus type 1 envelope V3 region isolates from mothers and infants after perinatal transmission. J Virol 1995; 69:1001 - 12; PMID: 7815476
   PubMed Web of Science ®Google Scholar
• Newell ML, Coovadia H, Cortina-Borja M, Rollins N, Gaillard P, Dabis F, Ghent International AIDS Society (IAS) Working Group on HIV Infection in Women and Children. Mortality of infected and uninfected infants born to HIV-infected mothers in Africa: a pooled analysis. Lancet 2004; 364:1236 - 43; http://dx.doi.org/10.1016/S0140-6736(04)17140-7; PMID: 15464184
   PubMed Web of Science ®Google Scholar
• Goonetilleke N, Liu MK, Salazar-Gonzalez JF, Ferrari G, Giorgi E, Ganusov VV, et al, CHAVI Clinical Core B. The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. J Exp Med 2009; 206:1253 - 72; http://dx.doi.org/10.1084/jem.20090365; PMID: 19487423
   PubMed Web of Science ®Google Scholar
• Keele BF, Giorgi EE, Salazar-Gonzalez JF, Decker JM, Pham KT, Salazar MG, et al. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A 2008; 105:7552 - 7; http://dx.doi.org/10.1073/pnas.0802203105; PMID: 18490657
   PubMed Web of Science ®Google Scholar
• Salazar-Gonzalez JF, Bailes E, Pham KT, Salazar MG, Guffey MB, Keele BF, et al. Deciphering human immunodeficiency virus type 1 transmission and early envelope diversification by single-genome amplification and sequencing. J Virol 2008; 82:3952 - 70; http://dx.doi.org/10.1128/JVI.02660-07; PMID: 18256145
   PubMed Web of Science ®Google Scholar
• Zhang LQ, MacKenzie P, Cleland A, Holmes EC, Brown AJ, Simmonds P. Selection for specific sequences in the external envelope protein of human immunodeficiency virus type 1 upon primary infection. J Virol 1993; 67:3345 - 56; PMID: 8497055
   PubMed Web of Science ®Google Scholar
• Zhu T, Mo H, Wang N, Nam DS, Cao Y, Koup RA, et al. Genotypic and phenotypic characterization of HIV-1 patients with primary infection. Science 1993; 261:1179 - 81; http://dx.doi.org/10.1126/science.8356453; PMID: 8356453
   PubMed Web of Science ®Google Scholar
• Wolinsky SM, Wike CM, Korber BT, Hutto C, Parks WP, Rosenblum LL, et al. Selective transmission of human immunodeficiency virus type-1 variants from mothers to infants. Science 1992; 255:1134 - 7; http://dx.doi.org/10.1126/science.1546316; PMID: 1546316
   PubMed Web of Science ®Google Scholar
• Dickover RE, Garratty EM, Plaeger S, Bryson YJ. Perinatal transmission of major, minor, and multiple maternal human immunodeficiency virus type 1 variants in utero and intrapartum. J Virol 2001; 75:2194 - 203; http://dx.doi.org/10.1128/JVI.75.5.2194-2203.2001; PMID: 11160723
   PubMed Web of Science ®Google Scholar
• Zhang H, Hoffmann F, He J, He X, Kankasa C, West JT, et al. Characterization of HIV-1 subtype C envelope glycoproteins from perinatally infected children with different courses of disease. Retrovirology 2006; 3:73; http://dx.doi.org/10.1186/1742-4690-3-73; PMID: 17054795
   PubMed Web of Science ®Google Scholar
• Wu X, Parast AB, Richardson BA, Nduati R, John-Stewart G, Mbori-Ngacha D, et al. Neutralization escape variants of human immunodeficiency virus type 1 are transmitted from mother to infant. J Virol 2006; 80:835 - 44; http://dx.doi.org/10.1128/JVI.80.2.835-844.2006; PMID: 16378985
   PubMed Web of Science ®Google Scholar
• Doms RW. Unwelcome guests with master keys: how HIV enters cells and how it can be stopped. Topics in HIV medicine: a publication of the International AIDS Society, USA 2004; 12:100-3.
   Google Scholar
• Kishko M, Somasundaran M, Brewster F, Sullivan JL, Clapham PR, Luzuriaga K. Genotypic and functional properties of early infant HIV-1 envelopes. Retrovirology 2011; 8:67; http://dx.doi.org/10.1186/1742-4690-8-67; PMID: 21843318
   PubMed Web of Science ®Google Scholar
• Wang S, Arthos J, Lawrence JM, Van Ryk D, Mboudjeka I, Shen S, et al. Enhanced immunogenicity of gp120 protein when combined with recombinant DNA priming to generate antibodies that neutralize the JR-FL primary isolate of human immunodeficiency virus type 1. J Virol 2005; 79:7933 - 7; http://dx.doi.org/10.1128/JVI.79.12.7933-7937.2005; PMID: 15919951
   PubMed Web of Science ®Google Scholar
• Wang S, Kennedy JS, West K, Montefiori DC, Coley S, Lawrence J, et al. Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers. Vaccine 2008; 26:3947 - 57; http://dx.doi.org/10.1016/j.vaccine.2007.12.060; PMID: 18724414
   PubMed Web of Science ®Google Scholar
• Wang S, Pal R, Mascola JR, Chou TH, Mboudjeka I, Shen S, et al. Polyvalent HIV-1 Env vaccine formulations delivered by the DNA priming plus protein boosting approach are effective in generating neutralizing antibodies against primary human immunodeficiency virus type 1 isolates from subtypes A, B, C, D and E. Virology 2006; 350:34 - 47; http://dx.doi.org/10.1016/j.virol.2006.02.032; PMID: 16616287
   PubMed Web of Science ®Google Scholar
• Vaine M, Wang S, Crooks ET, Jiang P, Montefiori DC, Binley J, et al. Improved induction of antibodies against key neutralizing epitopes by human immunodeficiency virus type 1 gp120 DNA prime-protein boost vaccination compared to gp120 protein-only vaccination. J Virol 2008; 82:7369 - 78; http://dx.doi.org/10.1128/JVI.00562-08; PMID: 18495775
   PubMed Web of Science ®Google Scholar
• Vaine M, Wang S, Hackett A, Arthos J, Lu S. Antibody responses elicited through homologous or heterologous prime-boost DNA and protein vaccinations differ in functional activity and avidity. Vaccine 2010; 28:2999 - 3007; http://dx.doi.org/10.1016/j.vaccine.2010.02.006; PMID: 20170767
   PubMed Web of Science ®Google Scholar
• Montefiori DC. (2004) Evaluating neutralizing antibodies against HIV, SIV and SHIV in luciferase reporter gene assays. Current Protocols in Immunology, (Coligan, J.E., A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W. Strober, and R. Coico, eds.), John Wiley & Sons, 12.11.1-12.11.15.
   Google Scholar
• Binley JM, Wrin T, Korber B, Zwick MB, Wang M, Chappey C, et al. Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J Virol 2004; 78:13232 - 52; http://dx.doi.org/10.1128/JVI.78.23.13232-13252.2004; PMID: 15542675
   PubMed Web of Science ®Google Scholar
• Brunel FM, Zwick MB, Cardoso RM, Nelson JD, Wilson IA, Burton DR, et al. Structure-function analysis of the epitope for 4E10, a broadly neutralizing human immunodeficiency virus type 1 antibody. J Virol 2006; 80:1680 - 7; http://dx.doi.org/10.1128/JVI.80.4.1680-1687.2006; PMID: 16439525
   PubMed Web of Science ®Google Scholar
• Muster T, Steindl F, Purtscher M, Trkola A, Klima A, Himmler G, et al. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J Virol 1993; 67:6642 - 7; PMID: 7692082
   PubMed Web of Science ®Google Scholar
• Gray ES, Meyers T, Gray G, Montefiori DC, Morris L. Insensitivity of paediatric HIV-1 subtype C viruses to broadly neutralising monoclonal antibodies raised against subtype B. PLoS Med 2006; 3:e255; http://dx.doi.org/10.1371/journal.pmed.0030255; PMID: 16834457
   PubMedGoogle Scholar
• Sanders RW, Venturi M, Schiffner L, Kalyanaraman R, Katinger H, Lloyd KO, et al. The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120. J Virol 2002; 76:7293 - 305; http://dx.doi.org/10.1128/JVI.76.14.7293-7305.2002; PMID: 12072528
   PubMed Web of Science ®Google Scholar
• Bublil EM, Yeger-Azuz S, Gershoni JM. Computational prediction of the cross-reactive neutralizing epitope corresponding to the [corrected] monclonal [corrected] antibody b12 specific for HIV-1 gp120. FASEB J 2006; 20:1762 - 74; http://dx.doi.org/10.1096/fj.05-5509rev; PMID: 16940148
   PubMed Web of Science ®Google Scholar
• Peters PJ, Duenas-Decamp MJ, Sullivan WM, Brown R, Ankghuambom C, Luzuriaga K, et al. Variation in HIV-1 R5 macrophage-tropism correlates with sensitivity to reagents that block envelope: CD4 interactions but not with sensitivity to other entry inhibitors. Retrovirology 2008; 5:5; http://dx.doi.org/10.1186/1742-4690-5-5; PMID: 18205925
   PubMed Web of Science ®Google Scholar
• Lu S, Wyatt R, Richmond JF, Mustafa F, Wang S, Weng J, et al. Immunogenicity of DNA vaccines expressing human immunodeficiency virus type 1 envelope glycoprotein with and without deletions in the V1/2 and V3 regions. AIDS Res Hum Retroviruses 1998; 14:151 - 5; http://dx.doi.org/10.1089/aid.1998.14.151; PMID: 9462925
   PubMed Web of Science ®Google Scholar
• Li M, Gao F, Mascola JR, Stamatatos L, Polonis VR, Koutsoukos M, et al. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol 2005; 79:10108 - 25; http://dx.doi.org/10.1128/JVI.79.16.10108-10125.2005; PMID: 16051804
   PubMed Web of Science ®Google Scholar
• Vaine M, Duenas-Decamp M, Peters P, Liu Q, Arthos J, Wang S, et al. Two closely related Env antigens from the same patient elicited different spectra of neutralizing antibodies against heterologous HIV-1 isolates. J Virol 2011; 85:4927 - 36; http://dx.doi.org/10.1128/JVI.00081-11; PMID: 21411542
   PubMed Web of Science ®Google Scholar
• Li M, Salazar-Gonzalez JF, Derdeyn CA, Morris L, Williamson C, Robinson JE, et al. Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa. J Virol 2006; 80:11776 - 90; http://dx.doi.org/10.1128/JVI.01730-06; PMID: 16971434
   PubMed Web of Science ®Google Scholar
• Seaman MS, Janes H, Hawkins N, Grandpre LE, Devoy C, Giri A, et al. Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. J Virol 2010; 84:1439 - 52; http://dx.doi.org/10.1128/JVI.02108-09; PMID: 19939925
   PubMed Web of Science ®Google Scholar
• Wei X, Decker JM, Wang S, Hui H, Kappes JC, Wu X, et al. Antibody neutralization and escape by HIV-1. Nature 2003; 422:307 - 12; http://dx.doi.org/10.1038/nature01470; PMID: 12646921
   PubMed Web of Science ®Google Scholar
• Gao F, Morrison SG, Robertson DL, Thornton CL, Craig S, Karlsson G, et al. Molecular cloning and analysis of functional envelope genes from human immunodeficiency virus type 1 sequence subtypes A through G. The WHO and NIAID Networks for HIV Isolation and Characterization. J Virol 1996; 70:1651 - 67; PMID: 8627686
   PubMed Web of Science ®Google Scholar
• Moodley D, Moodley J, Coovadia H, Gray G, McIntyre J, Hofmyer J, et al, South African Intrapartum Nevirapine Trial (SAINT) Investigators. A multicenter randomized controlled trial of nevirapine versus a combination of zidovudine and lamivudine to reduce intrapartum and early postpartum mother-to-child transmission of human immunodeficiency virus type 1. J Infect Dis 2003; 187:725 - 35; http://dx.doi.org/10.1086/367898; PMID: 12599045
   PubMed Web of Science ®Google Scholar
• Lu S, Manning S, Arthos J. Antigen engineering in DNA immunization. Methods Mol Med 2000; 29:355 - 74; PMID: 21374335
   PubMedGoogle Scholar
• Wang S, Farfan-Arribas DJ, Shen S, Chou TH, Hirsch A, He F, et al. Relative contributions of codon usage, promoter efficiency and leader sequence to the antigen expression and immunogenicity of HIV-1 Env DNA vaccine. Vaccine 2006; 24:4531 - 40; http://dx.doi.org/10.1016/j.vaccine.2005.08.023; PMID: 16140431
   PubMed Web of Science ®Google Scholar
• Montefiori DC, Metch B, McElrath MJ, Self S, Weinhold KJ, Corey L, HIV Vaccine Trials Network. Demographic factors that influence the neutralizing antibody response in recipients of recombinant HIV-1 gp120 vaccines. J Infect Dis 2004; 190:1962 - 9; http://dx.doi.org/10.1086/425518; PMID: 15529261
   PubMed Web of Science ®Google Scholar